Gender & Health

Spiraling prices for new cancer therapies - up to $10,000 a month for a single drug - are causing alarm among patients and insurance companies. Read More

Jurors in a state court in Houston decided yesterday that Johnson & Johnson, the consumer health care company, must pay $772,500 to the family of a Texas woman who died after a patch intended to release pain-killing drugs leaked. Read More

The Florida Supreme Court upheld today a decision that threw out a $145 billion judgment against the nation's largest tobacco companies. Read More

Patients who took the painkiller Vioxx were at risk of heart attacks and strokes - something shown by studies conducted years before the product went on the market, a doctor testified Wednesday. Read More

As Merck & Co. defends itself against a deluge of litigation involving its pain reliever Vioxx, the pharmaceutical giant also is fielding the first of what could be another wave of lawsuits involving Fosamax, its second-biggest seller. Read More

Around the country, doctors in private practice have set up tax-exempt charities into which drug companies and medical device makers are, with little fanfare, pouring donations - money that adds up to millions of dollars a year. And some medical experts see that as a big problem. Read More

The Consumers International lobby group accused drugmakers of using the methods to get doctors to prescribe products and persuade consumers they need them. Read More

Drug companies are accused today of endangering public health through widescale marketing malpractices, ranging from covertly attempting to persuade consumers that they are ill to bribing doctors and misrepresenting the results of safety and efficacy tests on their products. Read More

A correction published Monday to a key study on withdrawn painkiller Vioxx reveals the risk of heart problems was elevated throughout the time people were on the drug and did not develop only after 18 months of use as the drug's maker, Merck & Co., has contended. Read More

A major drug company is blocking access to a medicine that is cheaply and effectively saving thousands of people from going blind because it wants to launch a more expensive product on the market. Read More